Compatibility Study In-Vitro Drug Release Study of Solid Lipid Nanoparticle Based Transdermal Drug Delivery System for Rasagiline Mesylate

Transdermal drug delivery system (TDDS) is the dosage forms which deliver a therapeutically effective amount of drug across a patient's skin. The Solid lipid nanoparticles were successfully developed for rasagiline mesylate. SLN dispersions were prepared by melt emulsification and solidification at low temperature method. Compatibility between Drug and polymer study by FTIR. DSC and in-vitro release profile were carried out. In the Transdermal Drug Delivery System, Formulations F1-F9 was prepared by solvent casting method using 1.5%, 2.5% and 3.5% of HPMC K4M and 20%, 30% and 40% (w/w of dry polymer) of PEG 400. The formulation F5 was selected as the promising formulation on the basis of cumulative % drug release. The cumulative % drug diffused of F5 was found to be 89.55 ± 1.983. Further, the patch was found to be free of skin irritation. From the results stability study it can be concluded that the patches can be stored at 40°C and 75% RH without any significant stability problems. The formulation satisfied all the pharmaceutical parameters of transdermal films and appears to be promising.